POAI · Predictive Oncology Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $78.3K | $826.1K | $634.8K | $505.1K | $487.0K | $447.2K |
| Gross Profit | - | $797.7K | $1.15M | $1.00M | $933.7K | $805.1K |
| R&D | $2.15M | $26.0K | $188.3K | $320.3K | $315.9K | $372.7K |
| SG&A | $25.92M | $7.42M | $9.43M | $11.11M | $10.93M | $10.35M |
| Total Operating Expenses | $10.39M | $11.74M | $27.03M | $3.80M | $2.70M | $2.35M |
| D&A | $129.0K | $162.1K | $739.3K | $1.31M | $1.34M | $1.02M |
| Operating Income | ($180.92M) | ($10.94M) | ($14.08M) | ($26.03M) | ($20.43M) | ($25.36M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | ($661.7K) | $0 |
| Net Income | ($233.10M) | ($12.66M) | ($13.98M) | ($25.74M) | ($19.66M) | ($25.88M) |
| EPS - Basic | ($13.37) | ($2.32) | ($3.48) | ($0.36) | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.79M | $734.7K | $8.73M | $22.07M | $28.20M | $678.3K |
| Accounts Receivable | $32.1K | $745.6K | $333.7K | $331.2K | $354.2K | $256.9K |
| Inventory | - | $385.7K | $494.4K | $430.5K | $387.7K | $289.5K |
| Accounts Payable | $1.84M | $1.14M | $1.34M | $943.5K | $1.02M | $1.37M |
| Current Assets | $42.77M | $2.23M | $10.08M | $23.36M | $29.46M | $1.51M |
| Total Assets | $52.89M | $4.97M | $14.42M | $25.73M | $43.77M | $13.06M |
| Current Liabilities | $4.27M | $3.59M | $3.95M | $3.88M | $3.24M | $9.34M |
| Long-term Debt | - | - | - | - | $0 | - |
| Total Liabilities | $5.17M | $5.18M | $6.15M | $3.97M | $3.51M | $10.42M |
| Stockholders' Equity | $47.72M | ($202.6K) | $8.27M | $21.77M | $40.27M | $2.64M |
| Retained Earnings | ($413.52M) | ($180.43M) | ($167.76M) | ($153.78M) | ($128.04M) | ($108.38M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.88M) | ($10.97M) | ($13.19M) | ($12.37M) | ($12.21M) | ($12.26M) |
| Investing Cash Flow | ($32.62M) | ($9.5K) | ($302.4K) | ($475.7K) | ($10.61M) | ($167.5K) |
| Financing Cash Flow | $52.01M | $3.94M | $148.9K | $6.72M | $50.34M | $12.95M |
| CapEx | $0 | $9.5K | $276.4K | $419.9K | $910.4K | $298.4K |
| Free Cash Flow | ($9.88M) | ($10.98M) | ($13.47M) | ($12.79M) | ($13.12M) | ($12.56M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.04 | 0.87 | 0.96 | 0.50 | 0.67 | 0.49 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -440.7% | -254.7% | -97.0% | -100.0% | -44.9% | -198.2% |
| Return on equity | -488.5% | 6250.6% | -169.1% | -118.2% | -48.8% | -979.5% |
| Return on invested capital | - | - | - | - | -40.1% | - |
| Liquidity | ||||||
| Current ratio | 10.02 | 0.62 | 2.55 | 6.02 | 9.09 | 0.16 |
| Quick ratio | 10.02 | 0.51 | 2.43 | 5.91 | 8.97 | 0.13 |
| Cash ratio | 2.53 | 0.20 | 2.21 | 5.68 | 8.70 | 0.07 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.00 | - |
| Debt / Assets | - | - | - | - | 0.00 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.11 | -24.54 | 1.74 | 1.18 | 1.09 | 4.94 |
| Liabilities / Assets | 0.10 | 1.04 | 0.43 | 0.15 | 0.08 | 0.80 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | 2.14 | 1.28 | 1.17 | 1.26 | 1.54 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | 170d | 284d | 311d | 291d | 236d |
| Days payable outstanding | 8582d | 505d | 772d | 682d | 766d | 1120d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -30.4% | 14.5% | 7.1% | 16.0% | -8.5% |
| Operating income growth (YoY) | -1553.8% | 22.3% | 45.9% | -27.4% | 19.4% | -222.6% |
| Net income growth (YoY) | -1740.6% | 9.4% | 45.7% | -30.9% | 24.1% | -156.6% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 10.1% | 18.4% | -5.3% | 2.5% | -4.5% | -43.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -62.0% | -45.9% | 1423.7% | -76.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$459.4K totalEagan$459.4K · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Finance Services
Comparing Predictive Oncology Inc. against the 5 most active filers in the same SIC group.